Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Bevacizumab (Primary) ; Olaparib (Primary) ; Antineoplastics
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PAOLA-1; PAOLA-1/ENGOT-ov25
- 01 Nov 2023 Results published in the Oncogene
- 06 Jun 2023 Results of PAOLA-1 ancillary study assessing BRCA1 and RAD51C methylation analysis were presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results assessing Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial, presented at the 59th Annual Meeting of the American Society of Clinical Oncology